| scholarly article | Q13442814 |
| P50 | author | Gyeong Hoon Kang | Q56613348 |
| P2093 | author name string | Kyung Chul Moon | |
| Nam-Yun Cho | |||
| Baek-Hee Kim | |||
| Minhee Choi | |||
| Yong-Mee Cho | |||
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| Estimation of cancer deaths in Korea for the upcoming years | Q34658503 | ||
| DNA hypermethylation status of multiple genes in prostate adenocarcinomas | Q44083581 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1858-1862 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | BRAF and KRAS mutations in prostatic adenocarcinoma | |
| P478 | volume | 119 |
| Q33872795 | A novel method for somatic transgenesis of the mouse prostate using the Sleeping Beauty transposon system |
| Q36977833 | AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. |
| Q36216904 | Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients |
| Q37255151 | Advancing precision medicine for prostate cancer through genomics |
| Q24299235 | An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB |
| Q38661520 | Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy |
| Q36243554 | B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer |
| Q35656395 | BRAF Mutations in Canine Cancers |
| Q33392719 | BRAF activation initiates but does not maintain invasive prostate adenocarcinoma |
| Q35802430 | BRAF gene: From human cancers to developmental syndromes |
| Q37772444 | BRAF, a target in melanoma: implications for solid tumor drug development |
| Q37661831 | BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study |
| Q46207286 | Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations |
| Q90981691 | Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approaches |
| Q37458788 | Differential requirement for MEK Partner 1 in DU145 prostate cancer cell migration |
| Q39804717 | Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades |
| Q35176093 | Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity |
| Q54494653 | Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. |
| Q27860458 | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma |
| Q33977056 | Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance |
| Q91665731 | Molecular Status of BRAF Mutation in Prostate Adenocarcinoma: The Analysis of 100 Cases in North-East of IRAN |
| Q54373177 | Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). |
| Q36957578 | Oncogenic BRAF-Mediated Melanoma Cell Invasion |
| Q82644957 | PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events |
| Q90579775 | Polyacrylamide/Phytic Acid/Polydopamine Hydrogel as an Efficient Substrate for Electrochemical Enrichment of Circulating Cell-Free DNA from Blood Plasma |
| Q33918198 | Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy |
| Q34409739 | Prospective enterprise-level molecular genotyping of a cohort of cancer patients |
| Q38321512 | Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. |
| Q35871737 | Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells |
| Q33992803 | Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma |
| Q35742514 | Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. |
| Q36157012 | Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease |
| Q90223268 | Targeted next-generation sequencing for locally advanced prostate cancer in the Korean population |
| Q39294398 | Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy |
| Q35292006 | The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells |
| Q38058243 | The complexity of prostate cancer: genomic alterations and heterogeneity. |
| Q47379977 | The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? |
| Q55461604 | The diagnostic role and clinical relevance of determination of BRAF status in brain tumors. |
| Q42174920 | The genomic landscape of prostate cancer |
| Q33835864 | The molecular basis for ethnic variation and histological subtype differences in prostate cancer |
| Q34724225 | Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice |
| Q46590868 | Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology |
Search more.